identified three immune methylation patterns (IMPs) that can be used to construct a signature scoring model based on six genes (MYC, COL13A1, UHRF2, MT1A, ACTB, and GBP1) to predict osteosarcoma prognosis (99). This evidence concerns the gene UHRF2 and osteosarcoma.